VERAXA Biotech AG (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company's BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines. These innovations reinforce the company's long-term strategy to develop next-generation oncology therapeutics.
According to the press release, the expanded patent portfolio supports VERAXA's proprietary BiTAC technology, which includes bispecific T cell engagers and bispecific ADCs. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. BiTAC is a registered trademark of VERAXA Biotech GmbH.
For more information, visit the company's newsroom at http://ibn.fm/VRXA. The full press release can be viewed at https://ibn.fm/BqhFS.
